The
objective of this study is to measure the splenic volume of patients on
oxaliplatin therapy, using AUBMC’s new software (ISP upgrade), before and
during chemotherapy to detect any increase in splenic size as a biomarker for
early oxaliplatin toxicity. Also, we will measure liver scarring/fibrosis through transient elastography (FibroScan machine) as a
way to assess oxaliplatin induced liver injury. These two techniques will then
be compared to determine if liver injury detected by FibroScan precedes that
detected by measuring an increase in spleen size Other clinical
indicators of oxaliplatin toxicity will also be measured to study any possible
correlation between the grading of adverse events like peripheral neuropathy or
increase in transaminases and the occurrence and severity of
oxaliplatin-mediated increase in splenic size.
·
Measure the
splenic volume of patients on oxaliplatin therapy, using AUBMC’s new software
(ISP upgrade), before and during chemotherapy to detect any increase in splenic
size as a biomarker for early oxaliplatin toxicity.
·
Using liver
FibroScan, measure liver elasticity and controlled attenuated parameter (CAP)
before and during chemotherapy to detect liver fibrosis as a potential
biomarker for early Oxaliplatin toxicity.
·
Measure splenic
volume after discontinuation of oxaliplatin chemotherapy to assess for
reversibility of oxaliplatin- induced increase in splenic size, if any.
·
Measure other
clinical indicators of oxaliplatin toxicity to study any possible correlation
between the grading of adverse events like peripheral neuropathy or increase in
transaminases and the occurrence and severity of oxaliplatin-mediated increase
in spleen size.
·
Measure
synthetic liver functions (PT, PTT, albumin…), before, during, and after
Oxaliplatin therapy
·
Measure liver
elasticity and CAP after discontinuation of Oxaliplatin to assess reversibility
of Oxaliplatin-induced liver fibrosis, if already present.
·
In case of
patients undergoing surgery:
-Measure
portal venous pressure through transhepatic or transvenous catheterization
of the portal vein.
-Examine
liver for oxaliplatin induced injury (fibrosis/cirrhosis) by immunohistochemistry.